Clinical trials: Empagliflozin
Diabetes Mellitus, Type 2, Hypertension
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure.
- Conditions
- Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
- Trial name
- NCT07064473
- Testing
- Vicadrostat, Empagliflozin
- Where
- 1,142 sites in United States, Argentina and 49 more
- Volunteers
- 11,800 people
- Sponsor
- Boehringer Ingelheim
Glomerulonephritis, Immunoglobulin A Nephropathy
Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.
Idiopathic immunoglobulin A nephropathy (IgAN) is the most common biopsy-proven glomerulonephritis in the world. Approximately 40% of IgAN patients reach end-stage kidney disease (ESKD) 20 years after their kidney biopsy.
- Trial name
- CLIgAN (NCT04662723)
- Testing
- Corticosteroid, Renin-angiotensin sytem blockers, Sodium-glucose cotransporter 2 inhibitor
- Where
- 2 sites in Italy
- Volunteers
- 878 people
- Sponsor
- Fondazione Schena
Healthy
Relative Bioavailability of BI 10773 Administered Twice Daily Compared BI 10773 Given Once Daily After Multiple Oral Doses in Healthy Male and Female Volunteers
To investigate the influence of different dosage regimen (5 mg twice daily versus 10 mg once daily) on the steady state pharmacokinetics and pharmacodynamics of BI 10773 administered orally
- Trial name
- NCT02782624
- Testing
- Empagliflozin
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Type2 Diabetes, Insulin Sensitivity
Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes
The aim is to test in T2DM patients, whether, compared to placebo, 12 weeks of SGLT-2 inhibitor improves post-absorptive, post-insulin infusion or postprandial insulin action to enhance Cardiac Muscle vascular function and…
- Trial name
- EJB051 (NCT04203927)
- Testing
- Empagliflozin 25 MG
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Virginia
Diabetes After Total Pancreatectomy
Involvement of Dipeptidyl Peptidase-4 and Sodium-glucose Co-transporter-2 in Extrapancreatic Glucagon Secretion
Glucagon is a 29-amino acid peptide hormone of essential importance for glucose homeostasis. Hitherto glucagon has been believed to be secreted only from the pancreas, but recent studies show that glucagon is also secreted from…
- Trial name
- Px-Meal (NCT04061473)
- Testing
- Sitagliptin 100mg, Empagliflozin 25 MG
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Heart Failure
the Clinical Outcome of Empagliflozin in Pediatric Heart Failure Patients
the study to investigate the efficacy of empagiflozin in pediatric heart failure
- Trial name
- NCT07692256
- Testing
- Empagliflozin (EMPA), Standard medical treatment
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Type2 Diabetes
Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetES
The current study aims to explore the clinical effects and mechanistics of mono- and combination therapy with SGLT-2 inhibitor empagliflozin and DPP-4 inhibitor linagliptin on renal physiology and biomarkers in metformin-treated…
- Trial name
- RACELINES (NCT03433248)
- Testing
- EMPA/LINA 10/5 mg QD (n=22), LINA/EMPA 5/10 mg QD (N=22), Gliclazide 30 mg QD/BID (N=22)
- Where
- Netherlands
- Volunteers
- 66 people
- Sponsor
- M.H.H. Kramer
Autosomal Dominant Polycystic Kidney Disease
Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease
This study aims to better understand electrolyte handling in patients with autosomal dominant polycystic kidney disease treated with the SGLT2 inhibitor Empagliflozin.
- Trial name
- SIDIA (NCT06435858)
- Testing
- Empagliflozin
- Where
- 2 sites in Switzerland
- Volunteers
- 16 people
- Sponsor
- Cantonal Hospital Graubuenden
Myocardial Infarction (MI), Diabete Type 2
The Effect of Sodium Glucose Co-trnasportert Type 2 Inhibitors on Arterial Stiffness, Endothelial Glycocalyx Thickness and Cardiac Deformation After Acute Myocardial Infarction
Acute myocardial infarction (MI) remains one of the leading causes of cardiovascular morbidity and mortality worldwide. It most commonly occurs due to acute coronary artery occlusion following rupture or erosion of an…
- Trial name
- SGLT2i-MI-glyc (NCT07469943)
- Where
- Greece
- Volunteers
- 80 people
- Sponsor
- University of Athens
Acute Ischemic Stroke
SLGT2i for Neuroprotection in Patients With Acute Ischemic Stroke
Stroke is a leading cause of disability and mortality globally. With population aging, ischemic stroke (80% of cases) has become China's primary cause of adult disability.
- Trial name
- NCT07105917
- Testing
- SGLT-2 inhibitors, Standard medical treatment
- Volunteers
- 1,050 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Gestational Diabetes
Empagliflozin and the Preservation of Beta-cell Function in Women with Recent Gestational Diabetes
Double-blind, parallel arm, randomized controlled trial, in which non-lactating women with recent GDM who are between 6 to 36 months postpartum to be randomized to either empagliflozin 10 mg daily or matching placebo.
- Trial name
- EMPA post-GDM (NCT03215069)
- Testing
- Empagliflozin 10 MG
- Where
- Canada
- Volunteers
- 91 people
- Sponsor
- Mount Sinai Hospital, Canada
Rheumatoid Arthritis (RA)
Evaluation of Dapagliflozin and Empagliflozin as Adjunctive Therapy to Methotrexate in Patients With Rheumatoid Arthritis
This study aims to evaluate the efficacy and safety of dapagliflozin and empagliflozin as adjunctive therapies to methotrexate in patients with rheumatoid arthritis who have active disease despite stable methotrexate treatment.
- Trial name
- NCT07864688
- Testing
- Dapagliflozin, Empagliflozin, Methotrexate
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Al-Azhar University
Type 2 Diabetes Mellitus (T2DM), Cardiovascular Diseases
Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCl 25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR 25 mg/5 mg/1000 mg Extended- Release Tablets
An open label, randomized, two-period, two treatment, two-sequence, crossover, balanced, single dose oral bioequivalence study to compare Empagliflozin/ Linagliptin/ Metformin HCl 25 mg/5 mg/1000 mg Extended Release Tablet versus…
- Trial name
- NCT07691203
- Testing
- Empagliflozin/Linagliptin/Metformin HCl Extended Release Tablet, Trijardy® XR Tablets
- Where
- India
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Diabetes Mellitus, Type 2, Hyperglycemia
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
This study will investigate the efficacy and safety of two doses (high and low) of empagliflozin in combination with metformin (500 mg and 1000 mg) administered twice daily in patients with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01719003
- Testing
- Metformin 500 mg bid, Metformin 1000 mg bid, Empagliflozin low dose qd
- Where
- 190 sites in United States, Brazil and 19 more
- Volunteers
- 1,413 people
- Sponsor
- Boehringer Ingelheim
SGLT-2 Inhibitors, Advanced Glycation End Products
The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products
Single-center open-label multiple dose randomized two period cross-over study to examine Advanced Glycation End Product (AGE) levels in human subjects pre and post empagliflozin administration.
- Conditions
- SGLT-2 Inhibitors, Advanced Glycation End Products, Diabetes
- Trial name
- NCT02768220
- Testing
- empagliflozin, linagliptin
- Volunteers
- healthy volunteers welcome
- Sponsor
- Northwell Health
Type 2 Diabetes Mellitus (T2DM)
Bioequivalence Study to Compare Empagliflozin + Linagliptin 25 mg/5 mg Film-coated Tablets Versus Glyxambi 25 mg/ 5 mg Film-coated Tablets
An open label, balanced, randomized, single dose, two treatment, two sequence, two period, two way crossover oral bioequivalence study in healthy, adult, human subjects under fasting condition.
- Trial name
- NCT06932159
- Testing
- Empagliflozin + Linagliptin film-coated tablets, Glyxambi film-coated tablets
- Where
- India
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Healthy Volunteers
Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers
The purpose of this study is to compare the pharmacokinetics and safety of HD-P023 and coadministration of Teneligliptin and Empagliflozin in healthy adult volunteers
- Trial name
- NCT06339788
- Testing
- HD-P023, Teneligliptin, Empagliflozin
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Handok Inc.
Diabetes Mellitus, Type 2
Pharmacodynamics and Pharmacokinetics of Empagliflozin and Torasemide in Patients With Type 2 Diabetes
The primary objective of the study is to investigate the effect of BI 10773, hydrochlorothiazide and torasemide on changes in serum and urine electrolytes.
- Trial name
- NCT01276288
- Testing
- BI 10773, hydrochlorothiazide, torasemide
- Where
- Germany
- Volunteers
- 23 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes
This clinical trial aims to evaluate and compare the comparative efficacy and safety of Metformin-Empagliflozin-Sitagliptin vs. Metformin-Empagliflozin-Linagliptin in newly diagnosed Type 2 Diabetes Mellitus patients.
- Trial name
- NCT07452913
- Testing
- Metformin+ Empagliflozin + Sitagliptin, Metformin + Empagliflozin + Linagliptin
- Where
- Pakistan
- Volunteers
- 110 people
- Sponsor
- Bahria University
Brugada Syndrome (BrS)
Empagliflozin as a Potential Therapeutic Solution for Patients With Brugada Syndrome
The goal of this clinical trial is to learn if Empagliflozin works to treat Brugada syndrome patients by affecting their electrocardiographic (ECG) patterns, and to evaluate its safety.
- Trial name
- NCT07146880
- Testing
- Empagliflozin (EMPA)
- Where
- Taiwan
- Volunteers
- 10 people
- Sponsor
- National Taiwan University Hospital